Wave Plans One Two-Year Trial To Seek Both Fast-Track And Full Approval Of Its AATD Drug

After meeting the FDA, Wave says one registrational study of WVE-006 can serve both approval routes, with no separate confirmatory trial.

Share
Wave Plans One Two-Year Trial To Seek Both Fast-Track And Full Approval Of Its AATD Drug

Wave Life Sciences, a clinical-stage biotech that builds RNA medicines, said on its third-quarter earnings call on October 27 that a single registrational trial of WVE-006 could win both accelerated and full approval for alpha-1 antitrypsin deficiency (AATD), following a recent FDA meeting. The company says no separate confirmatory study will be needed.

One trial, two approval routes

Chief Medical Officer Chris Wright said Wave is planning "a single two-year registrational trial with a one-year interim analysis for potential accelerated approval based on AETD biomarkers." He called the design an efficient path to full approval.

CEO Paul Bolno said the team "came back with a really innovative design that was efficient for patients, efficient from a capital standpoint." He said the one-year interim would be predicated on delivering an MZ-like result, meaning a profile like that of carriers with a low risk of lung and liver disease.

Wright described that as a 50% or greater increase in healthy M protein, lower Z protein, and a rise in M during infection or lung inflammation. He said Wave's Restoration II data already show all three.

Wright said the FDA's pulmonary division, which does not often review genetic medicines, was "particularly" excited about the approach. He also said the agency supported Wave's LC-MS assay, a lab test that measures the M and Z proteins.

Endpoints stay private

Asked what endpoints could support full approval, Wright said Wave is not disclosing them. He said FEV1, a lung-function measure, is not "a feasible endpoint" for AATD in a reasonable time frame with a reasonable number of patients. He pointed to CT densitometry, which he said has been used for approvals in Europe; the FDA is not quite there yet, he said.

Bolno said Wave will not "competitively disadvantage" itself on the biomarkers while others are still working out what regulators require.

A Mizuho analyst asked whether the FDA has drawn a line between RNA and DNA medicines, noting that Beam still appears to be negotiating a confirmatory trial. Bolno pointed to FDA harmonization efforts and credited Wave's strategy of locking down a path to full approval first and working backward.

Dose data and cash runway

Wave expects to share data from the 600 milligram monthly-dose cohort of WVE-006 in the fourth quarter. Wright said it will help set the dose and regimen for the pivotal trial.

The company reported $431.0 million in cash, equivalents and marketable securities as of September 30, which it says funds operations into the third quarter of 2028. Third-quarter revenue was $13.2 million, up from $7.6 million a year earlier, tied to its GSK collaboration, according to CFO Kyle Moran. Research and development spending rose to $53.8 million from $45.9 million.

Moran said Wave expects a $12 million milestone payment from GSK in the fourth quarter after GSK selected a development candidate. Future milestones are not in the runway.

Next week Wave holds its annual research day, and the 600 milligram WVE-006 data are due before the year ends.

Sources

More on Wave Life Sciences

All Wave Life Sciences (WVE) coverage →